RxDoctor Payments Data

Nichole Ford, MD

Family Medicine · Tyler, TXNPI 1760943310

Payments from drug & device makers

$6,295in general payments, 2019–2025

Across 388 payments — averaging $16.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$895
  • GSK$647
  • AstraZeneca$621
  • Novartis$465
  • Lilly USA, LLC$435
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$6,20599%
  • Education$901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,295 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$53,207
Medicare patients
160
Services billed
594

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$64,394
MounjaroTirzepatide29$39,976
JardianceEmpagliflozin32$33,411
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$18,837
RybelsusSemaglutide21$18,686
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$14,451
SymbicortBudesonide/Formoterol Fumarate15$3,573
Doxepin Hcl19$2,400
Albuterol Sulfate HfaAlbuterol Sulfate60$2,181
Gabapentin164$1,989
Atorvastatin Calcium169$1,670
Duloxetine Hcl60$1,337
Fluticasone Propionate66$1,257
Levothyroxine Sodium167$1,132
Solifenacin Succinate27$1,088

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,026$83,08080 claims
Lilly USA, LLCMounjaro$435$39,97629 claims
Boehringer IngelheimJardiance$47$33,41132 claims
GSKTrelegy Ellipta$647$18,83723 claims
AstraZenecaBreztri Aerosphere, Symbicort$621$18,02438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →